Recro Gainesville LLC

recrogainesville.com

Pharmaceuticals Company located in Gainesville GA. Recro Gainesville LLC is a solid dose Contract Development and Manufacturing company that specializes in DEA controlled substances and sustained release technologies.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

IAMA THERAPEUTICS PARTNERS WITH THE ITALIAN INSTITUTE OF TECHNOLOGY TO EMBARK ON LANDMARK RESEARCH ON NEUROSCIENCE DRUG DISCOVERY

IAMA Therapeutics | March 31, 2022

news image

IAMA Therapeutics, a Series A preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in the lives of individuals suffering from brain disorders, today announced a strategic collaboration with the IIT-Istituto Italiano di Tecnologia where they will design and profile new classes of compounds targeting cation cotransporters in the CNS area. This partnership consolidates a scientific collaboration ...

Read More

Pharmacy Market

NOVARTIS' SANDOZ SPOTLIGHTS IMPORTANCE OF GENERIC DRUGS IN NEW SOCIAL CAMPAIGN

Novartis | December 17, 2020

news image

Did you realize that 90% of remedies are composed for nonexclusive medications? Novartis' Sandoz is getting the news out about nonexclusive medication with such realities in its as of late dispatched "Request Generics" crusade. It's Sandoz's first significant instruction and mindfulness crusade via online media to advance the estimation of generics. The intended interest group is key partners—patients, clinicians, policymakers and payers—with mess...

Read More

CORONAVIRUS DRAWS ATTENTION TO FDA OVERSIGHT OF CHINESE DRUGS

Political News - POLITICO | February 07, 2020

news image

Lawmakers are raising concerns anew about the U.S. reliance on foreign drug manufacturing amid the Wuhan coronavirus outbreak that has pushed FDA inspectors out of China. The novel disease outbreak could spark medical product shortages if the epidemic is not resolved swiftly, experts say. The challenges come as Chinese drug manufacturing has been in Congress's spotlight following a series of warnings last year about contaminated batches of foreign-made drugs. “There is emerging and I t...

Read More

Business Insights

SANDOZ TARGETS GROWTH OPPORTUNITIES IN RESPIRATORY AND COMPLEX GENERICS THROUGH ACQUISITION OF RESPIRATORY DEVICE COMPANY COALESCE

Novartis Pharma AG | March 14, 2022

news image

Sandoz, a Novartis division, announced that it has successfully acquired the UK-based medical and drug delivery device development company, Coalesce Product Development Limited. Through this deal, Sandoz has acquired the significant capabilities and assets of Coalesce, which will help it build on its existing portfolio of respiratory medicines and further improve patient access to these high-quality, complex therapies. “Respiratory and co...

Read More
news image

Pharmacy Market

IAMA THERAPEUTICS PARTNERS WITH THE ITALIAN INSTITUTE OF TECHNOLOGY TO EMBARK ON LANDMARK RESEARCH ON NEUROSCIENCE DRUG DISCOVERY

IAMA Therapeutics | March 31, 2022

IAMA Therapeutics, a Series A preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in the lives of individuals suffering from brain disorders, today announced a strategic collaboration with the IIT-Istituto Italiano di Tecnologia where they will design and profile new classes of compounds targeting cation cotransporters in the CNS area. This partnership consolidates a scientific collaboration ...

Read More
news image

Pharmacy Market

NOVARTIS' SANDOZ SPOTLIGHTS IMPORTANCE OF GENERIC DRUGS IN NEW SOCIAL CAMPAIGN

Novartis | December 17, 2020

Did you realize that 90% of remedies are composed for nonexclusive medications? Novartis' Sandoz is getting the news out about nonexclusive medication with such realities in its as of late dispatched "Request Generics" crusade. It's Sandoz's first significant instruction and mindfulness crusade via online media to advance the estimation of generics. The intended interest group is key partners—patients, clinicians, policymakers and payers—with mess...

Read More
news image

CORONAVIRUS DRAWS ATTENTION TO FDA OVERSIGHT OF CHINESE DRUGS

Political News - POLITICO | February 07, 2020

Lawmakers are raising concerns anew about the U.S. reliance on foreign drug manufacturing amid the Wuhan coronavirus outbreak that has pushed FDA inspectors out of China. The novel disease outbreak could spark medical product shortages if the epidemic is not resolved swiftly, experts say. The challenges come as Chinese drug manufacturing has been in Congress's spotlight following a series of warnings last year about contaminated batches of foreign-made drugs. “There is emerging and I t...

Read More
news image

Business Insights

SANDOZ TARGETS GROWTH OPPORTUNITIES IN RESPIRATORY AND COMPLEX GENERICS THROUGH ACQUISITION OF RESPIRATORY DEVICE COMPANY COALESCE

Novartis Pharma AG | March 14, 2022

Sandoz, a Novartis division, announced that it has successfully acquired the UK-based medical and drug delivery device development company, Coalesce Product Development Limited. Through this deal, Sandoz has acquired the significant capabilities and assets of Coalesce, which will help it build on its existing portfolio of respiratory medicines and further improve patient access to these high-quality, complex therapies. “Respiratory and co...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us